Skip to content
Manufacturing, Medical Health Aged Care

Microban launches Ascera(TM): a patent-pending, cutting-edge antimicrobial technology inspired by nature

Microban International 2 mins read

Huntersville, NC Microban International is pleased to introduce its latest ground-breaking technology – Ascera™. This patent-pending, next generation antimicrobial technology uses an active ingredient inspired by nature*, and is designed for use in olefinic polymers and solvent-based coatings. Ascera is sustainable, metal free and less toxic than alternative technologies, and provides the lifelong antimicrobial product protection that Microban is known for around the world.

As the global leader in antimicrobial and odor-control technologies, Microban is committed to the development of solutions that support product sustainability by extending their useful lifetimes. Ascera exemplifies the company’s commitment to sustainability by offering lasting product protection while maintaining critical attributes, such as ease of incorporation, safe handling, and good chemical, thermal and UV stability. Ascera will perform for the product’s expected lifetime when applied according to Microban’s standards, effectively inhibiting the growth of odor-causing bacteria to prevent stains and premature aging of the finished product.

“Microban has always led the antimicrobial industry with technological innovations that contribute to product sustainability,” said Dr. Souvik Nandi, Vice President of R&D at Microban International. “In the past decade, regulatory and environmental groups have put increasing pressure on many of the antimicrobial chemistries that are currently used. As a result, Microban has invested significant resources in identifying naturally occurring solutions that are more sustainable and effective. We are very proud to roll out Ascera, which represents the culmination of many years of intensive research. This is the first of an exciting series of nature-inspired solutions that we will be launching in the next few years for different market segments and material types.”

“As the global leader in antimicrobial, odor-control and surface modification solutions, Microban is always standing at the forefront of the industry. As we work towards our vision of becoming the most trusted brand in ultimate cleanliness and product protection, we want the world to rely on Microban for best-in-class solutions.” Michael Ruby, President of Microban International, said. “Our R&D teams are laser-focused on developing a range of cutting-edge technologies that are nature inspired for the different market sectors we serve. Our partners look to us first for what is next. Ascera will help leading brands to create clean, odor-free and high value end-use products, which their customers will choose to support sustainability and live a clean and refreshing lifestyle."

Ascera is available to manufacturers in the U.S. and Asia, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/ascera and get in touch with a representative today!

*The Microban® technology used in this product is similar to acids found in nature and is used in multiple consumer product applications.


About us:

Company Website

https://www.microban.com/


Contact details:

Audrey Jestin at kdm communications limited,

St Neots, UK

+44 1480 405333

[email protected]

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:
  • Manufacturing
  • 17/12/2025
  • 11:20
LibertyStream Infrastructure Partners Inc.

CORRECTING and REPLACING LibertyStream Announces Closing of Second and Final Tranche of LIFE Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES DALLAS–BUSINESS WIRE– First paragraph, first sentence should read: 1,676,923…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.